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The adult forms of Tay-Sachs and Sandhoff dis-
eases result when the activity of b-hexosamini-
dase A (Hex) falls below10% of normal due to
decreased transport of the destabilized mutant
enzyme to the lysosome. Carbohydrate-based
competitive inhibitors of Hex act as pharmaco-
logical chaperones (PC) in patient cells, facili-
tating exit of the enzyme from the endoplasmic
reticulum, thereby increasing the mutant Hex
protein and activity levels in the lysosome
3- to 6-fold. To identify drug-like PC candidates,
we developed a fluorescence-based real-time
enzyme assay and screened the Maybridge li-
brary of 50,000 compounds for inhibitors of pu-
rified Hex. Three structurally distinct micromo-
lar competitive inhibitors, a bisnaphthalimide,
nitro-indan-1-one, and pyrrolo[3,4-d]pyridazin-
1-onewere identified that specifically increased
lysosomal Hex protein and activity levels in pa-
tient fibroblasts. These results validate screen-
ing for inhibitory compounds as an approach to
identifying PCs.
INTRODUCTION
Pharmacological chaperones (PC), as small molecule
therapeutics, represent a novel paradigm for the treat-
ment of disorders arising from mutations that destabilize
and thus reduce protein levels [1–3]. In these cases, the
mutation affects the equilibrium between the folded and
unfolded states of the protein, shifting it away from the
functional (folded) conformation. Improperly folded mu-
tant (or wild-type) proteins are then cleared by the ‘‘protein
quality control systems’’ (QC) associated with the syn-
thetic machinery in the cytosol and endoplasmic reticulum
(ER) [4]. By preferentially binding to the native-like struc-
ture of the mutant protein, PCs, typically compounds act-
ing as antagonists/inhibitors, shift the equilibrium backChemistry & Biology 14, 153–toward the functional conformation, which is deemed
‘‘competent for release’’ by the protein cells’ QC [5].
Depending on the target protein, this treatment has been
shown to result in increased levels of the functional mutant
protein in the cytosol [6], specific organelles (e.g., the lyso-
some) [2], or the cell surface [7].
The PC approach has been shown to successfully en-
hance the enzyme levels of five different mutant lysosomal
enzymes that lead to the chronic form of the lysosomal
storage disorders, GM2 gangliosidosis [8], Fabry [9],
Gaucher [10], and Morquio B diseases [11]. GM2 ganglio-
sidosis, arising from the neuronal storage of GM2 gangli-
oside (GM2), occurs in three variants: Tay-Sachs disease
(TSD), Sandhoff disease (SD), and the AB variant. The for-
mer two result from mutations in the evolutionarily related
hexa or hexb genes, encoding the a or b subunits, respec-
tively, of heterodimeric b-N-acetyl-hexosaminidase A
(Hex A, ab) [12]. Two other homodimeric Hex isozymes ex-
ist (i.e., Hex B [bb] and Hex S [aa]), but cannot utilize GM2
ganglioside as a substrate.
Whereas both the a and/or b active sites of dimeric Hex
can hydrolyze neutral synthetic N-acetyl hexosamine-ter-
minal substrates, only the a site of Hex A and Hex S can
efficiently utilize negatively charged substrates (e.g.,
6-sulphated GlcNAc [13, 14]). Therefore, total Hex activity
can be measured with 4-methylumbelliferyl b-N-acetyl-
glucosaminide (MUG), whereas 4-methylumbelliferyl b-
N-acetylglucosamine-6-sulfate (MUGS) is used to mea-
sure Hex A and Hex S activity [14]. Substrates based on
4-methylumbelliferone (MU) are available and used to
diagnose enzyme deficiencies in the other lysosomal stor-
age disorders (LSD).
The more common infantile TSD (ITSD) variant of GM2
gangliosidosis results from absent a subunits and ele-
vated amounts of Hex B, such that levels of total Hex
activity (MUG) are near normal. Less common is infantile
SD (ISD), resulting from an absence of b subunits and
very low levels of Hex activity associated with the unstable
Hex S isozyme. In contrast to the infantile forms, adult
TSD (ATSD) and adult SD (ASD) are chronic, slowly pro-
gressive, neurodegenerative diseases that vary in age
onset. In many cases, they are associated with missense164, February 2007 ª2007 Elsevier Ltd All rights reserved 153
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sidual activity (MUGS) and protein levels that are <10%,
but >2% of normal. The correlation between clinical phe-
notypes and residual activity indicates that there is a sur-
prisingly low critical threshold level of Hex A activity (i.e.,
the level of Hex A needed to prevent GM2 ganglioside
storage) of 10% of normal [15].
The majority of patients with ATSD possess a missense
mutation in exon 7 of the a subunit gene (i.e., aG269S [12]).
This and similar point mutations do not directly affect the
a-active site of Hex A or the interface between its a and
b subunits [13, 16], but are believed to result in increased
amounts of misfolded a-protein in the ER, which are in turn
retained by its QC and degraded [17]. Since only a small
proportion of the newly synthesized mutant a-precursor
can adopt the proper conformation necessary to form
heterodimers and become transport competent, there
are reduced levels of both Hex A activity and protein in
the lysosome.
Previously, we used conventional carbohydrate-based
Hex inhibitors (e.g., N-acetyl glucosamine thiazoline
[NGT]) to enhance the stability, protein levels, and enzyme
activity of mutant Hex A in ATSD fibroblasts, and Hex S
levels in ISD patient fibroblasts [8]. NGT is a stable thiazo-
line derivative of the oxazoline reaction intermediate
formed by lysosomal Hex and other members of glycoside
hydrolase family GH20 [18, 19]. The 3D structures of GH20
family members, human Hex (hHex) B [13, 20], hHex A
[16], Streptomyces plicatus Hex [21], and Serratia marce-
sans chitobiase [22], have been determined, the former
three in complex with NGT. Although these enzymes
have an overall identity of less than 25%, their active site
residues share greater than 95% identity, and are super-
imposable to less than 1.5 A˚ rmsd [13, 21].
In all examples to date, compounds acting as PCs in
cells have also been competitive inhibitors of the target
enzyme [2], their effectiveness often varying with the na-
ture of the mutation [23], but generally correlating with
their bioavailability and Ki [24]. Potential PCs have been
identified for only a minority of the 40 known gene prod-
ucts that, when mutated, can result in an LSD. High-
throughput screening (HTS) of small molecule libraries
has been used to identify specific drug-like inhibitory com-
pounds for proteins with [25] or without [26, 27] known
structures or mechanisms of action. It is proposed that
HTS of a library of compounds for inhibitors of the target
enzyme would also result in the identification of candidate
PCs, which could then be evaluated by a secondary live
cell-based assay. Thus, we developed a real-time MU-
based enzyme assay and coupled it with HTS, utilizing pu-
rified human placental Hex as a target to identify several
drug-like inhibitors. Subsequently, lysates from patient
cells grown in the presence of these compounds were
demonstrated to have enhanced levels of Hex A (ATSD)
or Hex S (ISD) activity and protein. This approach repre-
sents a facile and efficient strategy for identification of
candidate PCs in small molecule libraries for any lyso-
somal enzyme with an available MU-based substrate by
first screening for inhibitory compounds.154 Chemistry & Biology 14, 153–164, February 2007 ª2007 ERESULTS AND DISCUSSION
Development of an Assay to Continuously Monitor
Hex Activity
Conventional MU-based substrate assays for the known
lysosomal glycosidases are end-point assays, which are
less convenient for HTS because they are more prone to
false-positives (quenchers) or false-negatives (fluorescent
compounds) [28]. Consequently, we developed a real-
time MU-based enzyme assay and coupled it with HTS
of the 50,000 small-molecule compound Maybridge li-
brary to identify drug-like inhibitory compounds against
highly purified placental human lysosomal Hex.
As the MU fluorophore, released by Hex and other lyso-
somal enzymes, has a pKa of 7.8 that is higher than the
acidic pH optimums of these enzymes, an endpoint assay
was used. Recently, it has been shown that the released
MU fluorophore can be continuously and efficiently mon-
itored at an acidic pH by decreasing the excitation wave-
length from 365 nm to 330 nm [29], but with no change in
emission optimum (450 nm). With this assay, the rate of
MU hydrolysis was linear over 25 min, with an apparent
Km of 0.35 mM at room temperature. For the HTS, a lower
concentration of substrate was chosen (60 mM) to diminish
the quenching effects of the substrate [30].
Since all of the test compounds were dissolved in
DMSO, we checked for effects of DMSO on Hex A activity.
DMSO inhibited Hex A activity by more than 50% at the
concentrations at which the library compounds were
screened (compounds tested at 20 mM gave the equiva-
lent of 0.26 M DMSO in the assays) (Figure 1A). Further-
more, since Vmax remained constant, whereas Km
increased with increasing DMSO concentrations, DMSO
was found to be a competitive inhibitor of Hex (Figure 1A),
with a Ki of 0.17 ± 0.02 M.
Primary Biochemical Screen: Identification
of Candidate Hex Inhibitors
To identify inhibitors, the activity of purified hHex A was
evaluated in the presence of each of 50,000 compounds
from the Maybridge small-molecule library. Inhibitory
compounds in the library were expected to reduce the re-
sidual activity of Hex A relative to the residual activity of
the enzyme treated with DMSO (high controls). Despite
the fact that DMSO was a weak competitive inhibitor of
Hex A, the HTS was successful in identifying Hex inhibi-
tory compounds.
Replicate assays for each compound were plotted as a
single (x, y) coordinate (Figure 1B). The majority (>75%) of
these values differed by less than 1.4-fold, and fell near the
x = y diagonal (i.e., the replicates were generally reproduc-
ible). The average Z0 statistic [31] of 0.67 for the two repli-
cates was well within the acceptable range for a robust
and interpretable screen [32]. The statistical cut-off for
the ‘‘hit’’ threshold, based on the standard deviations of
the high (DMSO only) and low (NGT and DMSO) control
values, was determined to be 69%. Since this resulted in
>600 hits, the hit threshold was empirically set to 50%lsevier Ltd All rights reserved
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to be evaluated to a more manageable 64 (0.13% hit rate).
Secondary Screen: Validation of Candidate
Inhibitors from Primary Screen
By virtue of their semilogarithmic sigmoidal dose-
response curve, which is typical of an inhibitor, only 24
of the 64 hits were confirmed as bona fide inhibitors (Table
1). Interestingly, the 24 confirmed hits were also com-
pounds that replicated best in the primary screen. The in-
Figure 1. Primary Screen of a 50,000 Compound Maybridge
Library for Hex A Inhibitors in the Presence of DMSO, a Com-
petitive Inhibitor of Hex A
(A) The change in Km (gray bars) and Vmax (bars outlined in black)
versus increasing concentrations of DMSO (n = 3). Error bars refer to
standard deviation.
(B) A portion of the replicate plot of residual Hex A activity (0%–300%)
in the presence of individual compounds from the Maybridge library
(inset: entire replicate plot [0%–1200%] for all compounds). Diagonal
line denotes compounds with identical activities in both replicates.
The hit zone containing candidate inhibitory compounds and average
residual activity is denoted by the shaded box and filled circle, respec-
tively. Residual activity values for each compound are provided in the
Supplemental Data.Chemistry & Biology 14, 153hibitory activities of these compounds (Table 1) span three
orders of magnitude (i.e., one compound had an IC50 of
0.2 mM, two were >6 mM, 16 ranged from 12 to 79 mM,
and six ranged from 105 to 385 mM). These results confirm
the utility of coupling the real-time enzyme assay based on
4-MU substrates with HTS to identify inhibitory com-
pounds for Hex and other lysosomal enzymes from a li-
brary of small-molecule compounds.
Singleton compounds, which had an IC50 > 100 mM, or
had reactive groups (e.g., compound M-49773, which
bore a reactive thiol group [known to inactivate Hex]),
were not examined further. Similarly, cyclic thiol com-
pounds, represented by M-27352 and M-26024, were
eliminated from the study, as they have been found to
be promiscuous inhibitors, identified in other HTS using
different enzymes. Compounds such as M-28324 and
M-00659, which were difficult to dissolve and/or precipi-
tated readily in aqueous solutions above 10 mM, also
were not examined further.
The majority of compounds identified by HTS that
inhibited Hex were substituted bicyclic and tricyclic nitro-
gen-containing heterocycles. The structures of these
compounds differ greatly from known azasugar-based
Hex inhibitors, and represent novel scaffolds that could
be further optimized for use as specific Hex inhibitors.
Three of the 24 compounds, M-22971, M-31850, and
M-45373, were chosen to be evaluated in greater detail.
M-31850 had the lowest IC50 identified (200 nM), and three
additional, structurally related compounds (M-13862,
M-31867, and M-31860; i.e., bearing the 1,8 naphthalimide
moiety compounds) were also identified with IC50s >
10 mM. The other two compounds, M-22971, an indan-1-
one, and M-45373, bearing a pyrrolo[3,4-d]pyridazin-
1-one moiety, were found to have IC50s < 10 mM (1.8 and
5.8 mM IC50, respectively). Furthermore, compounds
M-31850 and M-22971 contained scaffolds found in the
drugs, Alrestatin [33] and Indacrinone [34], that have
been approved for use in humans. Although compound
M-22971 has a structure common to bidentate ligands
(i.e., one capable of binding a metal ion), Hex does not
require a metal ion for activity.
Inhibitory Activities of the HTS Inhibitors of Hex
toward Other Members of Glycosidase Family GH20
and Human O-GlcNAcase
In order to determine the selectivity of the HTS inhibitors,
their activities were evaluated against hHex A and hHex B,
Jack Bean Hex (JBHex), the plant ortholog of lysosomal
hHex, bacterial Hex from Streptomyces plicatus (SpHex),
and chitobiase B from Serratia marcesens (SmCHB); all
are members of the GH20 glycosidase family. Human
O-GlcNAcase (hOGN), a member of the GH84 family of
glucosaminidases that has a reaction mechanism similar
to Hex [35], was also tested with the HTS inhibitors (Table
2). Glycosidases in both of these families use substrate
assisted catalysis and are all inhibited by NGT to different
degrees [19, 21, 35].
Although all of the HTS inhibitors show activity toward
both Hex A and B isozymes, there was a 2-fold difference–164, February 2007 ª2007 Elsevier Ltd All rights reserved 155
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Identification Number and IC50 (mM) Values
M-00573 6.5 ± 4.3 M-00659 34 ± 21 M-02984 65 ± 99 M-19672 12 ± 14
M-22971 1.8 ± 2.6 M-26024 30 ± 6.7 M-26463 270 ± 256 M-26553 20 ± 7.2
M-27352 39 ± 52 M-27368 42 ± 92 M-28322 29 ± 9.1 M-28324 180 ± 105
M-28347 71 ± 25 M-31516 35 ± 35 M-31526 24 ± 4.0 M-31850 0.20 ± 0.14
M-31860 138 ± 111 M-31862 108 ± 53 M-31867 31 ± 15 M-32527 42 ± 69
M-34700 45 ± 12 M-35014 162 ± 94 M-37955 72 ± 32 M-38728 44 ± 62
M-42881 77 ± 54 M-44054 93 ± 82 M-45373 5.8 ± 0.44 M-49773 79 ± 35156 Chemistry & Biology 14, 153–164, February 2007 ª2007 Elsevier Ltd All rights reserved
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Hex Inhibitor Screen Yields Pharmaco-ChaperonesTable 2. Summary of IC50 Values for the Confirmed Inhibitory Compounds against Human Hex Isozymes, a Panel
of Family-20 Glucosaminidases, and O-GlcNAcase
Inhibitora hHexA hHexB JBHex SpHex SmHex hOGN
DMSO 350 ± 31 98 ± 20 300 ± 13 NI (380) NI (380) NA
NGT 0.00027b 0.00019b 0.00028c >0.020d >3.0d 0.00007e
M-22971f 0.027 ± 0.006 0.071 ± 0.01 0.23 ± 0.07 >1.0 NI (1.0) NI (2.0)
M-31850 0.0060 ± 0.0018 0.0031 ± 0.0015 0.28 ± 0.04g >0.5 NI (0.3) NI (1.0)
M-45373 0.020 ± 0.008 0.040 ± 0.05 NI (0.6) NI (0.6) NI (0.6) NI (2.0)
hOGN, human O-GlcNAcase; NA, not applicable; NI, noninhibitor. IC50 Values are presented (mM).
a Based on endpoint assay (1.6 mM MUG).
b Ki (mM) was determined with MUG substrate.
c Ki was determined with pNP-GlcNAc substrate [19].
d Highest concentration (mM) at which compound was evaluated.
e Ki (mM) as shown in Macauley et al. [35], Table 2.
f Based on 1.5 mM pNP-GlcNAc substrate.
g Incomplete dose-response curve; estimated IC50 (mM).in the IC50 values for the two isozymes. Thus, DMSO and
M-31850 have lower IC50 values for Hex B as compared
with Hex A, while the reverse is true for both M-22971
and M-45373. M-45373 did not display any inhibitory ac-
tivity toward JBHex, even at concentrations approaching
1 mM. Although the two HTS inhibitors, M-22971 and
M-31850, showed some activity toward SpHEx, their
IC50 values decreased more than 30- and 100-fold, re-
spectively, relative to hHex. Most significantly, none of
the HTS compounds M-22971, M-31850, or M-45373
showed any inhibitory activity toward hOGN, even though
this enzyme readily hydrolyzes MUG (Km = 0.43 mM)
and NGT functions as an effective competitive inhibitor
(Ki = 70 nM) [35]. None of the three HTS inhibitors, even
at concentrations approaching 1 mM, showed any inhibi-
tory activity toward an unrelated lysosomal glycosidase,
glucocerebrosidase (Cerezyme).
NGT, the compound mimicking the reaction intermedi-
ate common to all members of family 20 and 84 glycosi-
dases, showed the broadest range of inhibitory activity
against the enzymes listed in Table 2. This is not surpris-
ing, as NGT interacts only with the conserved residues
that directly participate in substrate binding and catalysis.
The specificity shown for the hHex isozymes by the com-
pounds identified through HTS suggests that they likely in-
teract with only a few of the same conserved active-site
residues, requiring interactions with other peripheral, non-
conserved residues at or near the active site of hHex A/B
for high affinity binding.
Evaluation of Chaperoning Potential of HTS Hex
Inhibitors in ISD Patient Fibroblasts
The ability of the HTS inhibitors to act as PCs was evalu-
ated using a cell line from a patient with ISD (i.e., only ex-
presses Hex S). This isozyme is intrinsically unstable and
was shown previously to be very responsive to the
chaperoning effects of NGT [8] (e.g., similar treatment of
ISD or ATSD with NGT resulted in a 6-fold increase in
Hex S activity, but only a 3-fold increase in Hex A activityChemistry & Biology 14, 153–1[8]). All three compounds, M-31850, M-22971, and
M-45373, produced a dose-dependent increase in MUG
hydrolysis (Hex S levels) in lysates from treated ISD cells
(Figure 2A). The increase was specific to Hex, as a similar
increase was not observed in hydrolysis of MUbGal by
lysosomal enzyme b-galactosidase (Figure 2B). Clearly,
the three inhibitory compounds function as specific PCs
for Hex.
Compared to NGT, which is most effective in enhancing
enzyme activities at 1 mM [8], both M-31850 and M-45373
were maximally effective as PCs at 100- and 10-fold lower
concentrations, respectively. In contrast, M-22971 pro-
duced a maximal response near 1 mM. Although effective
as PCs, the parallel decrease in relative activity of both
MUG and MUbGal seen at concentrations above 1 mM
are indicative of the cellular toxicity of M-31850 and M-
22971 at elevated levels. Bisnapthalimide compounds
are toxic to cells in the nanomolar to micromolar range,
depending on the number of amines and length of alkyl-
amine linker [36].
Treatment of ATSD Fibroblasts with HTS
Compounds Results in Increased Levels of Mature/
Proteolytically Processed a Subunit in Lysosomes
To demonstrate that the compounds identified by HTS
can enhance the functional levels of the G269S mutant
a subunit, ATSD patient fibroblasts were grown in the
presence of M-22971, M-31850, and M-45373 at concen-
trations shown to be optimal in ISD cells. Western blotting
with an anti-Hex A antibody showed that treatment of
ATSD fibroblasts with the HTS compounds resulted in in-
creased levels of a subunit (Figure 3A). In comparison to
untreated cells (media only), the DMSO- and HTS inhibi-
tor-treated cells showed increased levels of a 56 kDa
band, corresponding to the processed, mature a subunit
(am) found in wild-type fibroblasts. Densitometric quanti-
tation of the am band demonstrated a clear increase in
levels of a subunit protein that closely paralleled the
increase in specific MUGS activity found in the lysates of64, February 2007 ª2007 Elsevier Ltd All rights reserved 157
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DMSO is a weak competitive inhibitor of Hex, it also acted
as a weak PC, increasing the amount of am approximately
1.5-fold relative to untreated cells. However, one cannot
exclude the possibility that DMSO may enhance Hex ac-
tivity by other mechanisms, as it has been reported to en-
hance protein levels by acting as a nonspecific chemical
chaperone [37] and was found to increase mRNA levels
of IL-1b by augmenting promotor activity [38].
The proteolytic processing of lysosomal enzymes oc-
curs post-ER (i.e., in lysosomes or late endosomes [39,
40]). D’azzo et al. [41] previously demonstrated that the
aG269S Hex A is retained in the ER, resulting in barely de-
Figure 2. Dose-Dependent Increase inMUGActivityFollowing
Growth of ISD Fibroblasts in Media Containing HTS-Derived
Inhibitory Compounds
ISD fibroblasts were grown in media containing different concentra-
tions of M-22971, M-31850, M-45373, or DMSO for 5 days, lysed,
and MUGS or MUbGal activity determined (n = 4). The relative in-
creases in MUG (A) or MUbGal (B) hydrolysis were determined as:
(MU fluorescence of the inhibitor-treated cells)/(MU fluorescence of
mock [DMSO]-treated cells). Dashed line denotes no change in activ-
ity. Error bars refer to standard deviation.158 Chemistry & Biology 14, 153–164, February 2007 ª2007 Elstectable levels of am. Thus, the increased levels of am in
the presence of the HTS inhibitors suggests that the com-
pounds function as PCs, increasing the levels of a subunit
that can be transported from the ER to the lysosome.
To conclusively demonstrate that the inhibitor-treated
cells have increased levels of Hex A in the lysosomes, a ly-
sosome-enriched fraction was prepared from DMSO and
M-31850-treated fibroblasts (Figure 3C). This method has
been previously used to isolate an ER-depleted lysosomal
fraction by magnetic chromatography following labeling of
fibroblasts by iron-dextran colloid [8, 42]. There was an
approximately 10-fold increase in Hex (MUGS)- and acid
phosphatase (MUP)-specific activity in the lysosomal frac-
tion. More importantly, MUGS activity was increased
3-fold both in the postnuclear supernatant and lyso-
some-enriched fractions, consistent with the hypothesis
that increased levels of Hex A in treated cells are found
in the lysosome. The activity of lysosomal acid phospha-
tase was not significantly affected in either fraction from
M-31850-treated cells. Fibroblasts do not synthesize sig-
nificant levels of the higher gangliosides (e.g., GM1 gangli-
oside [43]). Thus, the ATSD and ASD cells used in this
study do not store appreciable amounts of GM2 ganglio-
side. However, our data strongly imply that patient cells
that do synthesize higher gangliosides (i.e., neurons)
would benefit from M-31850 treatment.
These results validate the approach for identifying novel
PC by first performing an HTS for Hex-inhibitory com-
pounds. The strongest inhibitors identified, M-22971,
M-31850, and M-45373, are structurally distinct from the
known hHex inhibitors, the majority of which are azasu-
gars [19, 44] and iminocyclitol derivatives [45]. These
HTS-derived inhibitors can serve as new, more drug-like
frameworks that can be further optimized by high-
throughput combinatorial chemistry [45]. This approach
could be applied to the naphthalimide derivatives, as
they can be readily synthesized via a straightforward,
single-step scheme [46].
Examination of the Mechanism by Which Compound
M-31850 Acts as a PC for Hex A
Bisnaphthalimide compound, M-31850, was examined in
greater detail in terms of its mechanism of binding, be-
cause (1) it was active in cells at the lowest concentration
of the HTS compounds examined, (2) several naphthali-
mide derivatives, Elinafide (LU79533), and Alrestatin had
been evaluated or approved for use in humans, and (3)
other naphthalimide congeners can be easily synthesized.
To confirm that M-31850 functions as a PC in a manner
similar to NGT (i.e., it binds at [or near] the active site
and is capable of increasing the stability of the enzyme
[8]), the effects of the compound on enzyme kinetics and
thermal denaturation were analyzed. M-31850 increased
the half-life of the mutant Hex A from ATSD cells more
than 2-fold at 44C relative to the enzyme heated in the
presence of DMSO (Figure 4A). It acts as a classic com-
petitive inhibitor of Hex (Km increases and Vmax is unaf-
fected by increasing amounts of M-31850), with a Ki of
0.8 ± 0.1 mM (Figure 4B).evier Ltd All rights reserved
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M-31862, and M-31867 (Tables 1 and 3) from the second-
ary screen had IC50 values that were at least 100-fold
higher than the bisnaphthalimide, M-31850 (Table 3). All
Figure 3. Increased MUGS Activity in Treated ATSD Fibro-
blasts Is Associated with an Increase in the Mature a Subunit
Protein and Levels of the Active Hex A Isozyme
(A) ATSD cells were treated for 5 days with DMSO (1%), NGT (1 mM),
M-31850 (0.002 mM), M-22971 (1 mM), or M-45373 (0.1 mM). Follow-
ing resolution of the a and b subunits by SDS-PAGE and subsequent
transfer to nitrocellulose, the blot was probed with rabbit polyclonal
anti-hHex A antibody. Positions of the lysosomally processed, mature
a subunits (am) and b subunits (bm) in mock (media) or inhibitor-treated
fibroblasts are denoted by arrows to the left of the blot. Position of
Mr markers are shown to the left of the blot.
(B) The increase in MUGS activity parallels the increase in amount of
mature a subunit from lysates of treated ATSD fibroblasts. The specific
MUGS activity (nanomoles MU released/mg total cell protein/hr) of ly-
sates used to produce the western blot in (A) is shown plotted (open
bars) adjacent to the optical density of the am band (filled bars) from
the western blot in (A).
(C) Increased MUGS (Hex A) activity is found in the lysosomal fraction of
M-31850-treated ATSD cells. Comparison of MUGS activity (nanomoles/
mg of total cell protein/hr) in the postnuclear supernatant (PNS) and lyso-
some (lyso)-enriched fractions from M-31850 (0.002 mM)-treated (filled
bar) ATSD fibroblasts. Error bars refer to standard deviation.Chemistry & Biology 14, 153of these derivatives contained a small hydrophobic group
N-linked to the underlying naphthalimide by a short alkyl
chain that lacked a secondary amine. Similarly, the de-
creased inhibitory activity of the mononaphthalimides,
BTB12933 and 5141402, further underline the importance
of the second naphthalimide moiety.
The critical role of the secondary amine group in the
linker bridging the two naphthalimide moieties was under-
scored by the loss of all inhibitory activity when it was re-
placed by an ether linkage in the analogous position in
compound 7916963. The behavior of this compound
suggests that the secondary amine in M-31850 may be
involved in the formation of a hydrogen bond with an un-
identified residue in Hex A. Although reduced more than
10-fold, the inhibitory activity of compound 5141402 sug-
gests that an analogously positioned hydroxyl group
could provide the necessary hydrogen atom. The impor-
tance of the N-alkylamine linker for inhibitory activity of
both the mono- and bisnaphthalimide derivatives, com-
pound 5141402 and M-31850, is reminiscent of recently
described iminocyclitol-based Hex inhibitors bearing an
N-alkylamine moiety [47].
The attenuated inhibitory activity of compound 5141402,
lacking the second naphthalimide, suggests that it may
provide additional hydrophobic contacts important for
high-affinity binding. It is surprising that there is an 8-
fold decrease in the inhibitory activity of LU79553, as it
bears two naphthalimide groups and the position of the
amine in the linker relative to the naphthalimide group is
identical to that in M-31850. This suggests that the two
naphthalimide groups must be spaced appropriately in
order to effectively bind Hex A. The second active site in
Hex A is not a candidate for the site that binds the second
naphthamide group in M-31850, as the measured distance
between the two active sites is more than 2.5 times the size
of the alkylamine linker in M-31850. However, the pro-
posed hydrophobic aglycon pockets just outside either
active site of Hex A [20, 47] remain possible candidates.
On the basis of the inhibitory activity of the naphthali-
mide derivatives in Table 2, and the fact that M-31850 is
a competitive inhibitor, the following binding model is pro-
posed. One of the naphthalimide groups binds directly in
the substrate binding pocket of Hex A, while the second
naphthalimide moiety binds to a secondary hydrophobic
patch (e.g., an aglycon binding site). An appropriately
sized linker between the two naphthalimide groups is
needed to span the two sites, and must also be able to
form a stabilizing hydrogen bond with an acidic acceptor
residue on the surface of Hex A.
Compound M-31850 was evaluated in greater detail in
part due to its close similarity to LU79553 (Elinafide),
which previously had been evaluated in phase-I clinical
trials as a solid tumor chemotherapeutic due to its DNA
intercalating ability and inhibitory activity against topoiso-
merase I [46]. Although Elinafide did not proceed further in
clinical trials [48, 49] due to its toxicity at therapeutic
doses, these results demonstrate the utility of using the in-
hibitory compounds as seeds to identify in-trial or FDA-
approved drugs. Since the goal of the HTS screen was–164, February 2007 ª2007 Elsevier Ltd All rights reserved 159
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fide would be expected to expedite the development of
therapeutics for the treatment of ATSD [50].
SIGNIFICANCE
In Tay-Sachs disease (TSD) and Sandhoff disease
(SD), inadequate levels of Hex A (ab-dimer) in the lyso-
some result in the intralysosomal accumulation of
GM2 ganglioside in neuronal cells. Although the
more common infantile forms have no residual en-
zyme activity, the late-onset, adult, and juvenile forms
have 2%–8% of normal activity. To date, carbohy-
drate-based inhibitors of Hex (e.g., NGT) act as phar-
macological chaperones (PCs), enhancing lysosomal
Figure 4. M-31850Attenuates ThermalDenaturation of HexA,
aGly269Ser Mutant at 44C and It Is a Competitive Inhibitor
(A) Partially purified mutant Hex A from ATSD fibroblasts was heated at
44C in the presence of DMSO (mock-treated; filled symbols) or differ-
ent concentrations of M-31850 (open symbols) for 10, 20, 30, 40, or
60 min. ‘‘Fraction remaining MUGS activity,’’ (y axis) was calculated
using the formula: (MU fluorescence of inhibitor-treated sample
heated for a given time)/(MU fluorescence of inhibitor-treated sample
left at 4C [time = 0 min]) (n = 3) (i.e., 1 = no change). Error bars refer to
standard deviation.
(B) The change in Km (gray bars) and Vmax (bars outlined in black)
versus inhibitor concentration is shown for M-31850 (n = 3) with
MUG substrate. Michaelis-Menten plots were used to determine Km
and Vmax in the absence and presence of increasing concentrations
of M-31850 (dissolved in water). Error bars refer to standard deviation.160 Chemistry & Biology 14, 153–164, February 2007 ª2007 ElsHex enzyme levels in cells of late-onset patients above
the 10% critical threshold.
We have developed a high-throughput screening
(HTS) method to identify novel drug-like inhibitors of
Hex utilizing a fluorescence-based real-time enzyme
assay. The simplicity and efficiency of this strategy
to identify inhibitors utilizing existing methylumbelli-
ferone-based substrates can be exploited to quickly
identify candidate drug-like PC for other lysosomal
storage disorders where there is a nonexistent or lim-
ited panel of inhibitory compounds available for the
deficient enzyme.
Three structurally distinct single-digit micromolar
Hex inhibitors were identified that did not inhibit other
lysosomalenzymesorneutral, cytosolicO-GlcNAcase.
Table 3. Inhibitory Activity of Naphthalimide
Derivatives against Purified Human HexA
ID Substituent (R) IC50 (mM)
Parenta b
PHG 00876 NI (200)c,d
M-31860 138 ± 111e
M-31862 108 ± 53e
M-31867 31 ± 15e
BTB12933 H 18 ± 1.5
5141402 16 ± 1.5
M-31850 0.6 ± 0.3
LU79953 4.6 ± 1.9
7916963 NI (200)
NI, noninhibitor.
a General structure naphthalimide derivatives evaluated.
b N-linked R groups from naphthalimide derivatives.
c Highest concentration at which compound was evaluated.
d IC50 values based on 0.06 mM MUG (continuous).
e IC50 values based on 0.06 mM MUG (endpoint).evier Ltd All rights reserved
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derivatives, these compounds consist of novel frame-
works found in FDA-approved drugs, such as Alresta-
tin and Indacrinone. All of the HTS-derived inhibitors
were shown to function as PCs, since they enhanced
the levels and activity of Hex S and mutant Hex A in
infantile SD and adult TSD (ATSD) patient fibroblasts,
respectively. Importantly, the approximately 3-fold
increase in protein and enzyme activity levels in the
lysosomes from M-32850-treated ATSD cells would
be expected to raise Hex A levels above the critical
10% threshold. These results validate the approach
of using HTS for inhibitory compounds to identify can-
didate drug-like PCs.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
A total of 50,000 drug-like compounds from the Maybridge collection
(Maybridge PLC, UK) were used in the initial screen. Compounds eval-
uated in the secondary screen and their derivatives were reordered
from Maybridge PLC (UK) or Chembridge (USA) and solubilized using
DMSO or water. Fluorogenic substrates purchased from Sigma
(USA) included 4-methylumbelliferyl b-D-glucopyranoside (MUbGlc),
4-methylumbelliferyl b-D-galactosaminide (MUbGal), 4-methylumbel-
liferyl phosphate (MUP), MUG, and MUGS. The colorimetric substrate
p-nitrophenol b-D-N-acetyl glucosaminide (Sigma) was also used to
monitor Hex A activity. Placental hHex A was prepared as previously
described [51], and NGT was synthesized and purified as previously
described [52, 19].
Cell Lines
The following cell lines were used: 1766 (ATSD) was from an 40-yr-
old female patient diagnosed with the chronic (adult) form of TSD
(kindly provided by Dr. J.R. Donat, University of Saskatchewan, Kins-
men Children’s Centre, Saskatoon, Saskatchewan, Canada) homozy-
gous for the aG269S mutation (Molecular Diagnostics Laboratory,
SickKids, Toronto, ON, Canada); 294 (ISD) was from an ISD patient,
homozygous for the 16 kb hexb deletion mutation [53, 54]. All cell lines
were grown in a-minimal essential media (a-MEM; Invitrogen, USA)
supplemented with 10% fetal calf serum (FCS; Sigma), and antibiotics
Penicillin/Streptomycin (Invitrogen, USA) at 37C in a humidified CO2
incubator.
Primary Screening
The statistical test resulting in the Z0 factor [31] measured the variabil-
ity of the rate values for Hex in the presence (low control) and
absence (high control) of the Hex inhibitor, NGT. To control for
plate-to-plate variability, enzyme activity was expressed according
to the equation:
RA =

r  mL
mH  mL

,100
where RA is residual activity, r is rate in the presence of the library com-
pound, mL is mean low control rate (i.e., activity in the presence of NGT
and DMSO), and mH is mean high control rate (i.e., activity in the pres-
ence of DMSO only). Reactions were set up in black-walled 384-well
plates with the SAGIAN Core System (Beckman Coulter, Inc. Fullerton,
CA, USA) equipped with an ORCA arm for labware transportation, a
Biomek FX with a 96 channel head for liquid handling, and an Analyst
HT (Molecular Devices Corp., Sunnyvale, CA, USA) for fluorescence
detection. All reactions were performed in duplicate (separate plates).
High controls (32 wells) consisted of Hex A (100 ng/ml) in citrate phos-
phate (CP) buffer containing 0.0025% human serum albumin (HSA)
and 2% DMSO. Low controls (32 wells) additionally contained NGT
at 360 mM. Test wells contained 20 mM of each library compound. ToChemistry & Biology 14, 153–take into account the effects of DMSO on enzyme activity, the ex-
pressed residual activity for the two replicates in Figure 1B was nor-
malized to 100% (100 3 [raw activity/mean activity]).
Secondary Screening
The dose-response curves of the 64 hits from the primary screen were
determined by the continuous MUG Hex assay in the presence of
seven concentrations (0.1–100 mM) of the putative inhibitor diluted in
DMSO. Data were fit to the equation:
v=
a
1+

½I
IC50
s
where v = background corrected reaction rate, a = the rate in the
absence of the inhibitor, [I] = the concentration of the inhibitor, and
s = the slope factor, with either Grafit (v.4.0.010; Erithacus Software,
Surrey, UK) or Kaleidagraph (Synergy Software, PA, USA), to calculate
IC50 values. Compounds exhibiting sigmoidal dose-response curves
were selected as bona fide inhibitors.
Hex Activity Assays
Hex A/B/S activity was measured by release of 4-methylumbelliferyl
fluorophore from MUG. Total assay volume was 50 ml, and contained
10 mM citrate-phosphate buffer, pH 4.3, 0.025% HSA. For enzyme ac-
tivity monitored continuously, reactions were initiated with 75 mM MUG
at room temperature and monitored for 7 min with 330 nm and 450 nm
excitation and emission filters, respectively. For the endpoint assay,
the reaction at 37C was terminated by raising the pH to 10.5, above
the pKa of 4-MU, with 0.1 M 2-amino 2-methyl 1-propanol. The
increase in fluorescence was measured using a Spectramax Gemini
EM MAX (Molecular Devices Corp, Sunnyvale, CA) fluorometer, and
detected at excitation and emission wavelengths set to 365 nm and
450 nm, respectively.
Activity of JBHex (Vector Labs, USA) and SpHex (New England Bio-
labs, USA) in the presence of DMSO, NGT, and the HTS compounds
were evaluated identically to procedures used for hHex. In the case
of Serratia marcesens chitobiase (glucosaminidase) (kindly provided
by C. Vorgias [22, 55]), activity was monitored at pH 7.5 under other-
wise identical conditions. The activity of hOGN was performed with
0.5 mM, 4-nitrophenyl N-acetyl b-D-glucosaminide substrate and
reaction conditions as described by Macauley et al. [35].
For primary and secondary screening of the compounds, enzyme
activity was monitored continuously on the Analyst HT (Molecular
Devices Corp) fluorometer, as describe above. Steady-state kinetic
parameters were established with a range of MUG substrate (1.6–
0.003 mM) and enzyme concentrations (1–0.01 mg/ml). The inhibitory
activity of compounds that were fluorescent (M-31850 and derivatives)
or quenched (M-22971) near the emission maxima of MU were also
confirmed with the colorimetric substrate pNP-GlcNAc and conditions
described for the MUG endpoint assay, except that absorbance was
measured at 405 nm.
Kinetic parameters (Km, Vmax, and Ki) were determined by fitting the
nonlinear least square data to the Michaelis-Menten equation with
Kaleidagraph (Synergy Software) according to Kakkar et al. [56].
Heat Inactivation Assay
Heat inactivation experiments were performed with Hex A from ATSD
fibroblasts treated with NGT (1 mM) for 5 days, as previously described
[8], with Hex B removed by ion exchange chromatography. For heat in-
activation experiments, equal amounts of total protein (0.1–0.5 mg)
from enriched mutant Hex A fractions were diluted in CP buffer (pH
4.2), containing 0.5% HSA. Diluted samples of the enzyme containing
Hex inhibitors or DMSO were split into two aliquots; one was left on ice,
and the other heat-treated at 44C. The heat-treated enzyme was
cooled on ice until completion of the time series. For assaying enzyme
activity, samples were pre-equilibrated to 37C for 10 min, followed by
addition of MUGS substrate, and incubated at 37C for a further
30 min.164, February 2007 ª2007 Elsevier Ltd All rights reserved 161
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ISD fibroblasts were seeded onto 96 well tissue culture plates (Costar)
at 10,000–50,000 cells per plate (50% confluence). The following
day, the medium was replaced with fresh a-MEM-FCS with or without
a test compound to be evaluated (1:100 dilution). Test compounds
were either dissolved in water (NGT) or DMSO. Mock- or compound-
treated cells were evaluated in triplicate and grown for 5 days at
37C in a humidified CO2 incubator.
To measure Hex S activity in treated ISD fibroblasts, media was re-
moved, cells were washed twice with PBS, and subsequently lysed by
the addition of 10 mM citrate-phosphate buffer (pH 4.8), containing
0.1% HSA and 0.1% Triton X-100. One aliquot (25 ml) of the lysate
was mixed with an equal volume of MUG and assayed for total Hex ac-
tivity. To control for variability in cell numbers between replicate wells,
the remaining aliquot of the lysate was used to assay for lysosomal
b-galactosidase, with the substrate MUbGal [8] by the endpoint assay
described above.
Western Blotting
Lysates prepared from ATSD cells were subjected to SDS-PAGE on
a 10% bis-acrylamide gel, and the separated proteins were transferred
to nitrocellulose. A rabbit polyclonal antibody against hHex A was used
as previously described [57]. Blots were developed with chemilumi-
nescent substrate according to the manufacturer’s protocol (Amer-
sham, Bioscences, UK). Bands were visualized and optical density
quantitated using a high sensitivity gel documentation system (Fluor-
chem 8000) consisting of a cooled CCD camera coupled with Alpha
Innotech software (Alpha Innotech Corp., USA).
Purification of Iron-Dextran-Labeled Lysosomes
Lysosomal fractions were prepared from ATSD fibroblasts treated with
DMSO or M-31850 (1 mM) for 5 days, followed by labeling with iron-
dextran colloid and subsequent purification by magnetic chromatog-
raphy, as previously described [8]. Lysosomal, acid phosphosphase,
and Hex A were monitored fluorometrically with the substrates MUP
and MUGS, respectively, as previously described [8].
Mass Spectrometry
The mass of selected secondary hits was confirmed by the Advanced
Proteomic Centre at Sickkids (Toronto, ON, Canada) with a QToF mass
spectrometer (Waters/Micromass, Manchester, UK).
Supplemental Data
Supplemental Data are available online at http://www.chembiol.com/
cgi/content/full/14/2/153/DC1/.
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